Results from two new studies that have recently been published by medical journal The Lancet are a cause for celebration at Johnson & Johnson.
The studies, which concern the use of Johnson & Johnson and Bavarian Nordic's combined Ebola vaccine in Sierra Leone, show an immune response in 98 percent of participants 21 days after their second shot - the shot developed by Bavarian Nordic - but also that the vaccine is highly effective seven days after revaccination two years after the two introductory doses.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.